Product Details
| Product Name:
Melflufen |
CAS No.:
380449-51-4 |
| Purity:
97.05% |
Supply Ability:
10g |
| Release date:
2026/07/17 |
Product Introduction
Bioactivity
| Name | Melflufen |
| Description | Melflufen (Melphalan flufenamide), a dipeptide proagent of Melphalan, is an alkylating agent. Melflufen exhibits significant antitumor activity against multiple myeloma (MM) cells and has been shown to inhibit angiogenesis. Melflufen induces irreversible DNA damage and cytotoxicity in MM cells, thereby contributing to its antitumor efficacy. At equivalent molar concentrations, both the salt and free forms of Melflufen exhibit comparable biological activity. However, the salt form, Melflufen hydrochloride, typically demonstrates enhanced water solubility and stability, which may contribute to its increased therapeutic potential. |
| In vitro | Methods: Multiple myeloma cell lines including MM.1S, INA-6, RPMI-8226, MM.1R, Dox-40, ARP-1, and ANBL-6 were treated with Melflufen (0.5-10 μM, 24 hours), and cell viability was assessed via MTT assay.
Results: Melflufen demonstrated significant cytotoxicity across all the aforementioned multiple myeloma cell lines.[4] |
| In vivo | Methods: Melflufen (3 mg/kg, twice weekly for 2 weeks) was administered intravenously to CB-17 SCID mice, and tumor growth and survival were observed.
Results: Melflufen significantly inhibited MM tumor growth in vivo and prolonged the survival time of the mice.[4] |
| Storage | Keep away from moisture
Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | Prodrug J-1, Melflufen, Melphalan flufenamide | J-1 | J1 | J 1 |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Bioactive Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Peptide Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | NMPA-Approved Drug Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
-
CAS:1356841-17-2
$2180.00
-
-
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States